Highlights
- Market Cap
- $385.83B
- Enterprise Value
- $380.60B
- EPS (TTM)
- $2.38
- PE Ratio
- 91.23
- Total Revenue (TTM)
- $61.16B
- Gross Profit (TTM)
- $44.85B
- EBITDA (TTM)
- $28.29B
- Year Range
- $164.39 - $244.81
- Target Price
- $255.83
- ROA (TTM)
- 77.44%
- ROE (TTM)
- -162.60%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in AbbVie Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
AbbVie Inc. (ABBV) has returned -4.05% so far this year and 7.29% over the past 12 months. Looking at the last ten years, ABBV has achieved an annualized return of 19.07%, outperforming the S&P 500 Index benchmark, which averaged 12.16% per year.
AbbVie Inc.
- 1D
- 2.05%
- 1M
- -6.29%
- YTD
- -4.05%
- 6M
- -4.63%
- 1Y
- 7.29%
- 3Y*
- 15.00%
- 5Y*
- 19.40%
- 10Y*
- 19.07%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jan 2, 2013, ABBV's average daily return is +0.08%, while the average monthly return is +1.74%. At this rate, your investment would double in approximately 3.3 years.
Historically, 62% of months were positive and 38% were negative. The best month was Nov 2020 with a return of +22.9%, while the worst month was Mar 2018 at -18.3%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ABBV closed higher 54% of trading days. The best single day was Jan 26, 2018 with a return of +13.8%, while the worst single day was Jun 25, 2019 at -16.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.61% | 4.07% | -6.29% | -4.05% | |||||||||
| 2025 | 4.46% | 13.67% | 0.23% | -6.02% | -4.61% | -0.26% | 2.71% | 11.31% | 10.05% | -5.15% | 4.43% | 0.35% | 33.08% |
| 2024 | 7.10% | 7.09% | 3.44% | -9.85% | -0.86% | 6.38% | 9.04% | 5.93% | 0.60% | 4.06% | -10.27% | -2.86% | 18.86% |
| 2023 | -7.71% | 4.16% | 3.55% | -4.30% | -8.71% | -2.34% | 12.25% | -1.75% | 1.43% | -4.34% | 0.86% | 8.83% | -0.23% |
| 2022 | 2.15% | 7.95% | 9.70% | -8.62% | 0.33% | 3.93% | -5.42% | -6.31% | -0.19% | 10.19% | 10.10% | 0.27% | 24.01% |
| 2021 | -3.24% | 5.13% | 0.45% | 4.28% | 1.52% | -0.49% | 4.40% | 3.85% | -10.69% | 7.59% | 0.53% | 17.45% | 32.43% |
Benchmark Metrics
AbbVie Inc. has an annualized alpha of 13.33%, beta of 0.69, and R² of 0.20 versus S&P 500 Index. Calculated based on daily prices since January 03, 2013.
- This stock captured 123.01% of S&P 500 Index gains but only 89.73% of its losses — a favorable profile for investors.
- Beta of 0.69 may look defensive, but with R² of 0.20 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R² of 0.20 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 13.33%
- Beta
- 0.69
- R²
- 0.20
- Upside Capture
- 123.01%
- Downside Capture
- 89.73%
Return for Risk
Risk / Return Rank
ABBV ranks 48 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for AbbVie Inc. (ABBV) and compare them to a chosen benchmark (S&P 500 Index).
| ABBV | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.27 | 0.90 | -0.63 |
Sortino ratioReturn per unit of downside risk | 0.54 | 1.39 | -0.85 |
Omega ratioGain probability vs. loss probability | 1.07 | 1.21 | -0.14 |
Calmar ratioReturn relative to maximum drawdown | 0.53 | 1.40 | -0.87 |
Martin ratioReturn relative to average drawdown | 1.17 | 6.61 | -5.44 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore ABBV risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
AbbVie Inc. provided a 3.06% dividend yield over the last twelve months, with an annual payout of $6.65 per share. The company has been increasing its dividends for 12 consecutive years.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $6.65 | $6.56 | $6.20 | $5.92 | $5.64 | $5.20 | $4.72 | $4.28 | $3.59 | $2.56 | $2.28 | $2.02 |
Dividend yield | 3.06% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
Monthly Dividends
The table displays the monthly dividend distributions for AbbVie Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $1.73 | $0.00 | $0.00 | $1.73 | |||||||||
| 2025 | $1.64 | $0.00 | $0.00 | $1.64 | $0.00 | $0.00 | $1.64 | $0.00 | $0.00 | $1.64 | $0.00 | $0.00 | $6.56 |
| 2024 | $1.55 | $0.00 | $0.00 | $1.55 | $0.00 | $0.00 | $1.55 | $0.00 | $0.00 | $1.55 | $0.00 | $0.00 | $6.20 |
| 2023 | $1.48 | $0.00 | $0.00 | $1.48 | $0.00 | $0.00 | $1.48 | $0.00 | $0.00 | $1.48 | $0.00 | $0.00 | $5.92 |
| 2022 | $1.41 | $0.00 | $0.00 | $1.41 | $0.00 | $0.00 | $1.41 | $0.00 | $0.00 | $1.41 | $0.00 | $0.00 | $5.64 |
| 2021 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $1.30 | $0.00 | $0.00 | $5.20 |
Dividend Yield & Payout
Dividend Yield
AbbVie Inc. has a dividend yield of 3.06%, which is quite average when compared to the overall market.
Payout Ratio
AbbVie Inc. has a payout ratio of 206.96%, which is above the market average. This might signify the company's strong earnings or financial health. However, it could also hint at a more mature business phase with potentially slower growth.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the AbbVie Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the AbbVie Inc. was 45.09%, occurring on Aug 15, 2019. Recovery took 330 trading sessions.
The current AbbVie Inc. drawdown is 9.64%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -45.09% | Jan 29, 2018 | 390 | Aug 15, 2019 | 330 | Dec 4, 2020 | 720 |
| -31.61% | Jul 29, 2015 | 61 | Oct 22, 2015 | 383 | May 2, 2017 | 444 |
| -21.92% | Apr 11, 2022 | 120 | Sep 30, 2022 | 320 | Jan 10, 2024 | 440 |
| -20.74% | Mar 11, 2025 | 29 | Apr 21, 2025 | 94 | Sep 4, 2025 | 123 |
| -19.82% | Dec 8, 2014 | 43 | Feb 9, 2015 | 90 | Jun 18, 2015 | 133 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of AbbVie Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how AbbVie Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ABBV, comparing it with other companies in the Drug Manufacturers - General industry. Currently, ABBV has a P/E ratio of 91.2. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ABBV relative to other companies in the Drug Manufacturers - General industry. Currently, ABBV has a P/S ratio of 6.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |